Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy

Madeddu, Clelia; Deidda, Martino; Piras, Alessandra; Cadeddu, Christian; Demurtas, Laura; Puzzoni, Marco; Piscopo, Giovanna; Scartozzi, Mario; Mercuro, Giuseppe

Journal of Cardiovascular Medicine: May 2016 - Volume 17 - Issue - p e12–e18
doi: 10.2459/JCM.0000000000000376
Supplement Submission

The risk and mechanism of chemotherapy-induced cardiotoxicity (CTX) vary depending on the type and intensity of the anticancer regimen. Myriad chemotherapeutic drugs produce adverse cardiovascular effects such as arterial hypertension, heart failure, and thromboembolic events. Among the numerous classes of these drugs, anthracyclines have been studied most extensively because of their overt cardiovascular effects and the high associated incidence of heart failure. However, CTX might also be caused by other types of chemotherapeutic agents, including alkylating agents (cyclophosphamide, ifosfamide), platinum agents, antimetabolites (5-fluorouracil, capecitabine), antibiotics (mitoxantrone, mitomycin, bleomycin), and antimicrotubule agents (taxanes). Here, we review the incidence, clinical impact, and potential mechanisms of CTX associated with nonanthracycline chemotherapy used for cancer patients. The published data support a marked increase in CTX risk, particularly with certain drugs such as 5-fluorouracil and cisplatin. Each anticancer regimen is associated with distinct modes of heart damage, both symptomatic and asymptomatic. However, the underlying mechanisms of CTX have been established only in a few cases, and only few nonanthracycline chemotherapeutics (mitoxantrone, mitomycin, ifosfamide) act through a recognizable mechanism and show a predictable dose dependence. Lastly, nonanthracycline chemotherapy can induce both chronic lesions, such as systolic dysfunction, and acute lesions, such as the ischemia that occurs within hours or days after treatment. An increased understanding of the incidence, mechanisms, and potential therapeutic targets of CTX induced by various nonanthracycline chemotherapeutic agents is clearly required.

aDepartment of Medical Sciences Mario Aresu, Unit of Medical Oncology

bDepartment of Medical Sciences Mario Aresu, Unit of Cardiology and Angiology, University Hospital Cagliari, University of Cagliari, Cagliari

cDivision of Cardiology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’ – IRCCS, Naples, Italy

Correspondence to Dr Clelia Madeddu, Department of Medical Sciences Mario Aresu, Unit of Medical Oncology, University Hospital Cagliari, University of Cagliari, SS 554, Bivio Sestu, 09042 Monserrato, Cagliari, Italy. Tel: +39 70 675 4228; e-mail: clelia_md@yahoo.it

* Clelia Madeddu and Martino Deidda contributed equally to the preparation of the manuscript.

Received 27 January, 2016

Accepted 10 February, 2016

Article Outline
Back to Top | Article Outline

Introduction

Chemotherapy-induced cardiotoxicity (CTX) was defined by the Cardiac Review and Evaluation Committee of Trastuzumab-associated CTX as one or more of the following: a reduction in left ventricular ejection fraction (LVEF) from baseline by at least 5% to less than 55% in the presence of symptoms of heart failure or an asymptomatic reduction in LVEF by at least 10% to less than 55%; cardiomyopathy in terms of a reduction in LVEF, which can be either global or locally severe in the septum; and symptomatic heart failure.1 CTX is induced by anticancer therapy because of the redundancy of activity resulting from essential signaling pathways.2 Anticancer therapy exerts a combination of ‘on target’ effects, which counteract the undesirable proliferation of cancer cells, and ‘off target’ effects, which negate the protective effects of cardiomyocytes and endothelial cells, especially in response to stress.

CTX incidence and pathophysiology differ depending on the type, cumulative dose, and administration schedule of antiblastic therapy. The use of numerous chemotherapy drugs is associated with adverse cardiovascular effects such as congestive heart failure, myocardial ischemia, hypertension, thromboembolic complications, arrhythmias, and conduction disturbances. Among these drugs, anthracyclines have been studied most extensively because of their ability to induce cardiac injury, particularly heart failure. However, CTX might also be caused by other classes of chemotherapeutic agents (Table 1),3–34 such as alkylating agents (cyclophosphamide, ifosfamide), platinum agents, antimetabolites (5-fluorouracil, capecitabine), antibiotics (mitomycin, bleomycin), and antimicrotubule agents (taxanes).35

The cardiotoxic effects produced by antineoplastic agents can be permanent (type I CTX) or reversible (type II), and can be induced at distinct levels and intensities. A distinguishing feature of type I chemotherapy-induced CTX is the induction of cardiomyocyte injury.36 In terms of onset, CTX can develop in an acute, subacute, or chronic manner. Acute or subacute CTX is characterized by abnormalities of ventricular repolarization and electrocardiographic QT-interval changes, supraventricular and ventricular arrhythmias, or acute coronary syndromes and pericarditis and/or myocarditis-like syndromes, observed at any time from the initiation of therapy to as much as 2 weeks after treatment termination. Conversely, chronic CTX can be differentiated – based on the onset of clinical symptoms – into two subtypes: early, within 1 year after termination of chemotherapy; or late, more than 1 year after chemotherapy. The most typical sign of chronic CTX is asymptomatic systolic and/or diastolic LV dysfunction, which could lead to dilated cardiomyopathy. Nonanthracycline chemotherapy might induce chronic toxicity in the form of LV systolic dysfunction and also induce acute injuries such as ischemia, which occur within hours or days after the start of treatment.30 Moreover, current evidence indicates that the use of nonanthracycline chemotherapeutics is also associated with a CTX risk throughout the life of the patient.37

Back to Top | Article Outline

Pathophysiology

The mechanisms of CTX associated with nonanthracycline chemotherapeutics differ widely among several agents.38 One of these mechanisms is represented by the ability of the drugs to either directly damage cardiomyocytes or cause pericardium inflammation. For example, paclitaxel-induced CTX is mediated by direct damage of cardiac muscle cells through the drug's actions on subcellular organelles.39

In the case of 5-fluorouracil, the toxic effect exerted by the drug on the vascular endothelium involves the dysregulation of endothelial nitric oxide synthase and the induction of protein kinase C, and this leads to coronary spasms and endothelium-independent vasoconstriction.40

Certain drugs might affect the coagulation system and predispose to thromboembolic events. The coagulation cascade is altered mainly through damage of the vascular intima, which predisposes to thrombosis. Cisplatin, in particular, can enhance platelet aggregation and thromboxane formation, and activate arachidonic acid pathways.41

Anticancer agents might exacerbate atrial fibrillation, which could be a preexisting condition, especially in elderly cancer patients. Atrial fibrillation could be induced by ifosfamide, gemcitabine, melphalan, cisplatin, docetaxel, 5-fluorouracil, or etoposide.42

Other chemotherapeutic agents such as mitoxantrone, cyclophosphamide, cisplatin, and 5-fluorouracil might cause CTX by inducing mitochondrial dysfunction, similar to that observed with anthracyclines. The toxic effect produced on mitochondria arises from an impairment of the respiratory chain, oxidative phosphorylation, Krebs cycle, or β-oxidation, with a consequent increase of oxidative stress, reduction of antioxidant capacity, and induction of apoptosis.38

Back to Top | Article Outline

Drugs and mechanisms

Alkylating agents

Cyclophosphamide at high doses causes structural injury to the heart and then permanent damage (type I CTX).36 This lesion develops as an acute myopericarditis and can cause cardiac tamponade and arrhythmias. The risk of CTX is dose-dependent and CTX occurs within 1 to 10 days after administration of the first dose of the drug.7–9 High-dose cyclophosphamide is associated with an increased risk of heart failure, ranging from 7 to 28%.10

The exact mechanism of cyclophosphamide-induced CTX is unknown. The drug can produce direct endothelial damage, followed by extravasation of toxic metabolites that damage myocytes, interstitial hemorrhage, and edema. Ischemic myocardial injury could be the result of intracapillary microemboli.3 Moreover, cyclophosphamide impairs cellular respiration and damages the inner mitochondrial membrane of cardiomyocytes, most likely through the induction of oxidative stress.4

Cyclophosphamide is converted to the unsaturated aldehyde acrolein, a toxic, reactive metabolite that induces extensive protein modification and myocardial injury. Thus, the role of glutathione S-transferase P (GSTP), an acrolein-metabolizing enzyme, in cyclophosphamide CTX has been investigated. The results showed that following cyclophosphamide treatment, GSTP insufficiency was associated with increased accumulation of protein-acrolein adducts in the heart; this suggests that cyclophosphamide CTX is regulated – at least partly – by GSTP, which prevents drug toxicity by metabolizing and detoxifying acrolein.5

High-dose ifosfamide has been associated with severe but reversible myocardial depression and malignant arrhythmias. Ifosfamide is similar to cyclophosphamide, and thus it might induce CTX through a mechanism similar to that of cyclophosphamide CTX. However, no histopathological evidence of hemorrhagic myocarditis was found in ifosfamide-treated patients.43

Recent data from an animal-model study showed that both cyclophosphamide and ifosfamide treatment inhibit the expression in cardiac tissues of the genes that encode heart fatty acid-binding protein and carnitine palmitoyltransferase I, and, consequently, inhibit mitochondrial transport and long-chain fatty acid oxidation. The results revealed a parallel progressive increase in serum lactate dehydrogenase, creatine kinase isoenzyme myocardial band, and malonyl-CoA content and the development of histopathological lesions in cardiac tissues, and thus confirmed a potential contribution of these pathways to cyclophosphamide and ifosfamide-induced CTX.6

Back to Top | Article Outline

Platinum

Cisplatin is a potent chemotherapeutic agent that exhibits broad-spectrum antineoplastic activity against diverse tumors. However, a major factor that limits cisplatin treatment is the drug's acute and cumulative CTX, which includes ECG abnormalities, angina15 and acute myocardial infarction,16 hypertension17 and hypotension,18 arrhythmias, myocarditis, cardiomyopathy, and congestive heart failure.19 Platinum-based therapy has also been shown to increase the risk of thrombotic events in cancer patients.20

Cisplatin CTX can result either from a direct toxic action on cardiac myocytes or from reactive oxygen species (ROS) production, followed by the induction of oxidative stress and the switch to a prothrombotic condition.11 In an animal model, cisplatin induced a substantial increase in the plasma concentration of cardiac troponin I, which was associated with a marked increase in the malondialdehyde level, and, in parallel, a notable reduction in antioxidants (i.e. in glutathione content and superoxide dismutase activity) was observed; consequently, mitochondrial and nuclear DNA was heavily damaged.12 Another animal study revealed that cisplatin might lead to LV dysfunction and depressed cardiomyocyte contraction by inducing mitochondrial ultrastructural abnormalities, characterized by activation of the ER stress response and apoptosis.13

Platinum also induces platelet activation and aggregation, which potentially involves monocyte procoagulant activity and might alter endothelial cell integrity.14 Lastly, cisplatin might elevate the levels of von Willebrand factor, induce hypomagnesaemia and vasospasm, and trigger antiangiogenic activity.44–47

Cisplatin has been associated with a long-lasting profile of CTX, as reported in the case of survivors of testicular cancer,37 who showed an increased risk for myocardial infarction after treatment with cisplatin. In these patients, the plasma levels of cisplatin remain measurable for up to 20 years after completion of therapy and cause cumulative dysfunction of endothelial cells, which eventually detach from the vessel wall.48 Therefore, in this case, a long-lasting pharmacological signature (circulating cisplatin) correlates with molecular mechanisms of damage (endothelial dysfunction) and clinical events (myocardial infarction). Although circulating cisplatin is detectable in most of the survivors of testicular cancer, myocardial infarction occurs in 6% or fewer patients,49 which indicates high interpersonal variability in the response to cisplatin exposure.50

Back to Top | Article Outline

Antimetabolites

Cardiac toxicity of fluoropyrimidines is the second most common cause of chemotherapy-induced CTX.51 Most frequently, 5-fluorouracil causes angina-like chest pain; however, in rare cases, myocardial infarction, arrhythmias, ventricular tachycardia, heart failure and cardiogenic shock, and QT prolongation with torsades de pointes have been reported.25,26

The CTX incidence associated with 5-fluorouracil has been reported to vary from 1 to 68%.20 One prospective study determined that the incidence of capecitabine-associated CTX was 5.5%.52 A recent review53 assessed the CTX occurrence associated with 5-fluorouracil, capecitabine, or raltitrexed that was reported in articles published between January 1991 and August 2011; the finding was that the overall incidence of CTX associated with 5-fluorouracil/capecitabine varied between 0.55 and 19% (mean: 5.0%; median: 3.85%), but no CTX was associated with raltitrexed. Moreover, a meta-analysis reported an incidence of symptomatic CTX of 1.2 to 4.3% during treatment with 5-fluorouracil and suggested that the risk can be increased by continuous infusion and concurrent treatment with cisplatin.54

The pathogenic mechanism of CTX associated with 5-fluorouracil and capecitabine is unknown; however, coronary thrombosis, arteritis, and vasospasm have been proposed as possible mechanisms. Certain metabolites of 5-fluorouracil, particularly α-fluoro-β-alanine, have been shown to be associated with CTX. Thymidine phosphorylase is an enzyme involved in the conversion of capecitabine into 5-fluorouracil and of 5-fluorouracil into its active metabolites; the enzyme is an angiogenic factor55,56 whose expression is upregulated in atherosclerotic plaques and during myocardial infarction.21,22 Toxic effects of the drugs could also be caused through endothelial damage, with increased levels of endothelin 1 producing vasospasm and ischemia.

Additional hypothesized mechanisms of CTX are direct toxic effects of the drugs on the myocardium, interaction with the coagulation system, and autoimmune responses.52 A cardio-oncology study25 showed that 5-fluorouracil can induce apoptosis and autophagy through the production of oxidative stress in cardiomyocytes and endothelial cells. Moreover, Eskandari and colleagues23 conducted an animal-model study and demonstrated that the CTX resulting from 5-fluorouracil and capecitabine treatment was associated with the formation of ROS, lipid peroxidation, and a rapid depletion of glutathione; the resulting increase in oxidative stress was associated with mitochondrial dysfunction, which triggered caspase-3 activation and led to apoptosis or necrosis. Furthermore, 5-fluorouracil, but not capecitabine, caused lysosomal membrane leakage when incubated with cardiomyocytes.23 Conversely, studies on several animal models have suggested that another causative mechanism of CTX could be citrate accumulation in cardiomyocytes, attributed to the degradation of 5-fluorouracil into fluoroacetate, which interferes with the Krebs cycle.24,52 Accordingly, other studies have shown that 5-fluorouracil can induce dose and time-dependent depletion of high-energy phosphates in myocardial cells.57–59

Back to Top | Article Outline

Antibiotics

Mitoxantrone is a chemotherapeutic agent that can induce dose-dependent, irreversible CTX; the CTX risk is markedly increased after cumulative doses of at least 160 mg/m2 of the drug. Mitoxantrone might induce arrhythmias, chronic heart failure,30 and persistent diastolic dysfunction in the absence of an impairment of LVEF.31 The mechanisms of mitoxantrone-associated CTX remain incompletely understood, but one suggested mechanism involves the formation of ROS in myocardial cells through interactions with cellular iron metabolism, which leads to tissue damage.27

In an experimental animal model, mitoxantrone increased lactate levels and the activity of complexes IV and V of the mitochondrial respiratory chain, which underscores the role of mitochondriopathy in mitoxantrone-induced CTX.28 Moreover, a study conducted on H9c2 cells by using mitoxantrone at therapeutic concentrations showed that mitochondrial membrane potential and intracellular levels of ATP and calcium were changed; the authors concluded that the disruption of energy metabolism might be a key factor in mitoxantrone-induced cell damage.29

Bleomycin use is associated with pericarditis and coronary artery disease. Serosal inflammation in the form of acute pleuropericarditis might be part of the generalized mucocutaneous toxicity that is common during bleomycin therapy. Conversely, ischemic cardiomyopathy could be caused by the toxic and inflammatory effects of bleomycin on endothelial cells.60–62 Ultimately, this chemotherapy-induced cellular activation can progress to endothelial dysfunction, accelerated atherosclerosis, and overt CVD.

Notably, in patients with testicular cancer, myocardial infarction has been reported to potentially occur after a single dose of bleomycin, as well as years after completion of cumulative bleomycin regimens.63 Moreover, mitomycin C might lead to chronic heart failure, with the risk being increased after cumulative doses of at least 30 mg/m2.

Lastly, drugs belonging to this class might potentially induce cardiac damage through pathways related to an increase in oxidative stress, although by mechanisms that differ from those of anthracyclines.30

Back to Top | Article Outline

Antimicrotubule agents (paclitaxel and docetaxel)

In 5% of patients treated with paclitaxel, atrioventricular block, left bundle branch block, ventricular tachycardia, and ischemic cardiac events were observed, whereas asymptomatic bradycardia occurred in a variable proportion of patients (from <0.1 to 31%).33 Arrhythmias and conduction disorders were suggested to be potentially caused by the effects of paclitaxel on the Purkinje system or extracardiac autonomic control.32 After these adverse cardiac events were observed during the monitoring of patients, which was justified by the high incidence of serious hypersensitivity reactions induced by paclitaxel in phase I studies, clinical trials have excluded patients with a diagnosed heart disease and patients under any medication that could interfere with cardiac conduction.20

Among all antimicrotubule agents in clinical use, paclitaxel is formulated with the highest concentration per dose of Cremophor EL, which is recognized to induce the release of histamine; the released histamine, in turn, stimulates its specific cardiac receptors and increases the oxygen demand of the myocardium, and might lead to coronary vasoconstriction and chronotropic consequences.33 These effects, even in distinct combinations, might be responsible for the induction of myocardial ischemia observed in patients receiving paclitaxel treatment.20,33 Notably, paclitaxel, but not docetaxel, is able to delay the catabolism of doxorubicin, thus leading to a higher incidence, although not statistically significant, of reduction in LVEF.34,64

The incidence of docetaxel-associated heart failure has been documented to range from 1.6 to 2%,65,66 but the incidence of myocardial ischemia has been reported only in the drug's package insert (http://products.sanofi.us/Taxotere/taxotere.html). Notably, congestive heart failure has been observed in metastatic breast cancer patients who received prior adjuvant anthracycline therapy and when docetaxel was combined with trastuzumab treatment for human epidermal growth factor receptor 2-positive disease.66 Asymptomatic reductions in LVEF of at least 15% have been reported in 6–8% of the patients treated with docetaxel;66,67 this percentage is higher in patients pretreated with anthracycline and in those who received the trastuzumab–docetaxel combination for human epidermal growth factor receptor 2-positive metastatic breast cancer.66

Back to Top | Article Outline

Conclusion

The complex and heterogeneous mechanism of CTX, the large variability in the time of onset of cardiac injury, and the extremely variable clinical presentation – or even asymptomatic occurrence – of damages warrant an extensive cautionary cardiac surveillance of all cancer patients undergoing antineoplastic treatments. Specifically, we must deepen our knowledge of the incidence, mechanisms, and potential therapeutic targets of CTX induced by various nonanthracycline chemotherapeutic agents.68

Despite this background, the CTX induced by nonanthracycline chemotherapy is pleomorphic and remains poorly predictable; moreover, the mechanisms of CTX can be established with certainty only in a few cases. Accordingly, treatment with only a few nonanthracycline chemotherapeutic agents, such as mitoxantrone, mitomycin, and ifosfamide, leads to CTX in a recognizable dose and schedule-dependent manner.

In the absence of detailed information, for nonanthracycline chemotherapy drugs, the overall concept that applies is that preexisting comorbidities such as hypertension, diabetes, and hyperlipidemia, or unfavorable lifestyle choices such as reduced physical activity increase the risk of CTX.69 Consequently, asymptomatic, potentially reversible CTX resulting from ‘well tolerated doses’ of nonanthracycline chemotherapeutics might progress to symptomatic events by overlapping with other risk factors, according to the hypothesis that late-onset CTX builds on pharmacologic and nonpharmacologic sequential injuries.

In clinical practice, patients are typically treated with multiple, consecutive lines of chemotherapy regimens. Therefore, the possibility of a reciprocating interaction between drugs of distinct classes must be accounted for, as in the case of patients undergoing a cycle of anthracycline treatment in combination with nonanthracycline chemotherapy. The knowledge that oncologists and cardiologists gain regarding the pathophysiology of CTX induced by individual chemotherapeutic agents will help in improving the identification of the risk profile of each patient and in the planning of a preventive strategy that is as tailored as possible.

Back to Top | Article Outline

Acknowledgement

There are no conflicts of interest.

Back to Top | Article Outline

References

1. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215–1221.
2. Hahn VS, Lenihan DJ, Ky B. Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc 2014; 3:e000665.
3. Jones RL, Ewer MS. Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther 2006; 6:1249–1269.
4. Souid AK, Tacka KA, Galvan KA, Penefsky HS. Immediate effects of anticancer drugs on mitochondrial oxygen consumption. Biochem Pharmacol 2003; 66:977–987.
5. Conklin DJ, Haberzettl P, Jagatheesan G, et al. Glutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice. Toxicol Appl Pharmacol 2015; 285:136–148.
6. Sayed-Ahmed MM, Aldelemy ML, Al-Shabanah OA, et al. Inhibition of gene expression of carnitine palmitoyltransferase I and heart fatty acid binding protein in cyclophosphamide and ifosfamide-induced acute cardiotoxic rat models. Cardiovasc Toxicol 2014; 14:232–242.
7. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22:263–302.
8. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol 1991; 9:1215–1223.
9. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141:758–763.
10. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23 (Suppl 7):vii155–vii166.
11. Altena R, Hummel YM, Nuver J, et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011; 22:2286–2293.
12. El-Awady EE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650:335–341.
13. Ma H, Jones KR, Guo R, Xu P, Shen Y, Ren J. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol 2010; 37:460–465.
14. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998; 160:2021–2024.
15. Khan S, Chen CL, Brady MS, et al. Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma. J Clin Oncol 2012; 30:e163–e164.
16. Ryberg M. Recent advances in cardiotoxicity of anticancer therapies. Am Soc Clin Oncol Educ Book 2012; 32:555–559.
17. Amit L, Ben-Aharon I, Tichler T, Inbar E, Sulkes A, Stemmer SM. Cisplatin-induced posterior reversible encephalopathy syndrome – brief report and review of the literature. J Behav Brain Sci 2012; 2:97–101.
18. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 2008; 130:688–695.
19. Bano N, Najam R, Qazi F. Adverse cardiac manifestations of cisplatin - a review. Int J Pharm Sci Rev Res 2013; 18:80–85.
20. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53:2231–2247.
21. Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, et al. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: In vivo correlation of lesional microvessel density and constrictive vascular remodeling. Arterioscler Thromb Vasc Biol 1999; 19:2340–2347.
22. Hemalatha T, Balachandran C, Manohar BM, et al. Myocardial expression of PDECGF is associated with extracellular matrix remodeling in experimental myocardial infarction in rats. Biochem Cell Biol 2010; 88:491–503.
23. Eskandari MR, Moghaddam F, Shahraki J, Pourahmad J. A comparison of cardiomyocyte cytotoxic mechanisms for 5-fluorouracil and its pro-drug capecitabine. Xenobiotica 2015; 45:79–87.
24. De Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 1992; 10:1795–1801.
25. Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf 2009; 8:191–202.
26. Focaccetti C, Bruno A, Magnani E, et al. Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes. PLoS One 2015; 10:e0115686.
27. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 2005; 68:261–271.
28. Rossato LG, Costa VM, Dallegrave E, et al. Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. Cardiovasc Toxicol 2014; 14:30–40.
29. Rossato LG, Costa VM, Vilas-Boas V, et al. Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells as an earlier event. Cardiovasc Toxicol 2013; 13:413–425.
30. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol 2008; 21:978–989.
31. Joyce E, Mulroy E, Scott J, et al. Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction. J Card Fail 2013; 19:571–576.
32. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111:273–279.
33. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol 1991; 9:1704–1712.
34. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer 2003; 97:40–45.
35. Ai D, Banchs J, Owusu-Agyemang P, Cata JP. Chemotherapy-induced cardiovascular toxicity: beyond anthracyclines. Minerva Anestesiol 2014; 80:586–594.
36. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc 2014; 89:1287–1306.
37. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007; 25:3991–4008.
38. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010; 102:14–25.
39. Shek TW, Luk IS, Ma L, Cheung KL. Paclitaxel-induced cardiotoxicity. An ultrastructural study. Arch Pathol Lab Med 1996; 120:89–91.
40. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem 2006; 4:1–5.
41. Schimmel KJ, Richel DJ, Van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30:181–189.
42. Van der Hooft CS, Heeringa J, Van Herpen G, Kors JA, Kingma JH, Stricker BH. Drug-induced atrial fibrillation. J Am Coll Cardiol 2004; 44:2117–2124.
43. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118:31–36.
44. Icli F, Karaoguz H, Dincol D, et al. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer 1993; 72:587–593.
45. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19:1195–1206.
46. Zumkley H, Bertram HP, Preusser P, Kellinghaus H, Straub C, Vetter H. Renal excretion of magnesium and trace elements during cisplatin treatment. Clin Nephrol 1982; 17:254–257.
47. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979; 90:929–931.
48. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112:1949–1953.
49. Van den Belt-Dusebout AW, Nuver J, De Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24:467–475.
50. Peng B, Tilby MJ, English MW, et al. Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. Br J Cancer 1997; 76:1466–1473.
51. Sorrentino MF, Kim J, Foderaro AE, Truesdell AG. 5-Fluorouracil induced cardiotoxicity: review of the literature. Cardiol J 2012; 19:453–458.
52. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134:75–82.
53. Kelly C, Bhuva N, Harrison M, Buckley A, Saunders M. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer 2013; 49:2303–2310.
54. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev 2013; 39:974–984.
55. Bronckaers A, Gago F, Balzarini J, Liekens S. The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev 2009; 29:903–953.
56. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989; 338:557–562.
57. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol 1980; 30:871–879.
58. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13:797–801.
59. Freeman NJ, Costanza ME. 5-Fluorouracil-associated cardiotoxicity. Cancer 1988; 61:36–45.
60. Lechner D, Kollars M, Gleiss A, Kyrle PA, Weltermann A. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost 2007; 5:2445–2452.
61. Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23:247–253.
62. Ishii H, Takada K. Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NF-(B/Rel. Toxicol Appl Pharmacol 2002; 184:88–97.
63. Ozben B, Kurt R, Oflaz H, et al. Acute anterior myocardial infarction after chemotherapy for testicular seminoma in a young patient. Clin Appl Thromb Hemost 2007; 13:439–442.
64. Minotti G, Saponiero A, Licata S, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001; 7:1511–1515.
65. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302–2313.
66. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265–4274.
67. Sessa C, Pagani O. Docetaxel and epirubicin in advanced breast cancer. Oncologist 2001; 6 (Suppl 3):13–16.
68. Madonna R, Cadeddu C, Deidda M, et al. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev 2015; 20:621–631.
69. Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 2010; 334:2–8.
Keywords:

cardiotoxicity; 5-fluorouracil; oxidative stress; platinum; taxanes

© 2016 Italian Federation of Cardiology. All rights reserved.